Will Pfizer approach Viking Therapeutics with a buyout proposal?

Investors are running into Viking Therapeutics (NASDAQ: VKTX) this week after an incident of drug-induced liver injury pushed Pfizer (NYSE: PFE) into terminating the development of its weight-loss pill.Viking’s share price has gained % in recent sessions on speculation that PFE will now resort to an acquisition to expand its footprint in the weight-loss space.Viking Therapeutics is currently testing an oral as well as an injectable GLP-1 drug. Plus, its stock has tanked nearly 50% this year, which makes it ...